Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RBD SARS-CoV-2 HBsAg virus-like particle vaccine
- Development stage
- Unknown
- Lead developer
- Serum Institute of India
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The RBD SARS-CoV-2 HBsAg virus-like particle vaccine (LY01020) is a recombinant protein subunit vaccine candidate developed by Shandong Boan Biotechnology, a subsidiary of Luye Pharma. The vaccine utilizes a virus-like particle (VLP) platform where the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein is displayed on the surface of Hepatitis B surface antigen (HBsAg) particles. This multivalent presentation is designed to mimic the structure of a virus and enhance the B-cell response and overall immunogenicity compared to monomeric RBD proteins. The formulation includes two adjuvants: aluminum hydroxide (alum) and CpG 1018, a Toll-like receptor 9 (TLR9) agonist, to further boost the immune response and promote a Th1-biased profile. Clinical development has proceeded through Phase I/II trials in Australia, managed by the CRO Accelagen, evaluating the safety and immunogenicity of the vaccine in healthy adults.
- Other names
- RBD-HBsAg VLP vaccineRBD-based SARS-CoV-2 HBsAg VLP vaccineRBD SARS-CoV-2 HBsAg VLP vaccine
02
Targets
HBsAg (Hepatitis B surface antigen)ACE2 (Angiotensin-converting enzyme 2)RBD (SARS-CoV-2 spike receptor-binding domain)Naïve B-cell receptors specific for SARS-CoV-2 receptor-binding domain epitopes
Beyond the preview
Go deeper on RBD SARS-CoV-2 HBsAg virus-like particle vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RBD SARS-CoV-2 HBsAg virus-like particle vaccine.